JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
Perform high-precision, automated immunodiagnostic testing for every lab setup.
Achieve flexible and accurate molecular testing for targeted and syndromic applications.
Perform high-precision, automated immunodiagnostic testing for every lab setup.
Achieve flexible and accurate molecular testing for targeted and syndromic applications.
Attenzione, le pagine di questa sezione sono disponibili solo in lingua inglese.
By selecting the International view, you verify that you reside outside of the USA and you wish to view Diasorin's International Product Information.
This material is intended for International (non-USA) site visitors only.
Pursuant to the Guidelines of the Ministry of Health dated 28/03/2013 related to health advertising concerning medical devices, in vitro diagnostic medical devices and medical-surgical devices, we hereby inform you that the information contained in this website and to which you are going to access is exclusively intended for professional operators.

The first high-throughput, fully automated CLIA assay to quickly differentiate between bacterial and viral infections in a single procedure. Combining host-immune protein measurements it overcomes the diagnostic difficulties of traditional testing methods, making LIAISON® MeMed BV® ideal for patients with suspected acute infections.

LIAISON® QuantiFERON TB-Gold Plus is an IGRA based-test that drastically improves tuberculosis testing compared to traditional tests.

The first complete solution with optimal diagnostic performance for Bordetella pertussis diagnosis

Differential serological diagnosis of Mycoplasma Pneumoniae: a crucial step for effective patient management.

The first high-quality quantitative CLIA assay that assesses disease severity in patients with a suspected infection by detecting Mid-regional pro-adrenomedullin (MR-proADMTM) via a single test. It is ideal for patients with suspected acute infections at ED and ICU.

LIAISON® BRAHMS PCT® II Gen is a CLIA assay for the quantitative determination of procalcitonin in human serum and plasma specimens. The assay is intended for use, in conjunction with other laboratory findings and clinical assessments, to aid in the risk analysis for critically ill patients regarding the progression of relevant bacterial infections.

The first high-quality quantitative CLIA assay that assesses disease severity in patients with a suspected infection by detecting Mid-regional pro-adrenomedullin (MR-proADMTM) via a single test. It is ideal for patients with suspected acute infections at ED and ICU.

LIAISON® BRAHMS PCT® II Gen is a CLIA assay for the quantitative determination of procalcitonin in human serum and plasma specimens. The assay is intended for use, in conjunction with other laboratory findings and clinical assessments, to aid in the risk analysis for critically ill patients regarding the progression of relevant bacterial infections.

The first high-throughput, fully automated CLIA assay to quickly differentiate between bacterial and viral infections in a single procedure. Combining host-immune protein measurements it overcomes the diagnostic difficulties of traditional testing methods, making LIAISON® MeMed BV® ideal for patients with suspected acute infections.

LIAISON® QuantiFERON TB-Gold Plus is an IGRA based-test that drastically improves tuberculosis testing compared to traditional tests.

The first complete solution with optimal diagnostic performance for Bordetella pertussis diagnosis

Differential serological diagnosis of Mycoplasma Pneumoniae: a crucial step for effective patient management.